

1 **Equity in the effect of small-quantity lipid-based nutrient supplements on child**  
2 **growth, development and anemia**  
3  
4

5 Pearl Anne Ante-Testard<sup>1\*</sup>, Charles D. Arnold<sup>2</sup>, K. Ryan Wessells<sup>2</sup>, Seth Adu-Afarwuah<sup>3</sup>, Per  
6 Ashorn<sup>4,5</sup>, Elodie Becquey<sup>6</sup>, Kenneth H. Brown<sup>2</sup>, Parul Christian<sup>7</sup>, John M. Colford, Jr.<sup>8</sup>, Lia  
7 C.H. Fernald<sup>8</sup>, Emanuela Galasso<sup>9</sup>, Sonja Y. Hess<sup>2</sup>, Jean H. Humphrey<sup>7,10</sup>, Lieven  
8 Huybregts<sup>6</sup>, Lora L. Iannotti<sup>11</sup>, Stephen P. Luby<sup>12</sup>, Kenneth Maleta<sup>13</sup>, Clair Null<sup>14</sup>, Andrew J.  
9 Prendergast<sup>10,15</sup>, Ann M. Weber<sup>16</sup>, Hasnot Ali<sup>17</sup>, Shahjahan Ali<sup>18</sup>, Ulla Ashorn<sup>4</sup>, Jaden  
10 Bendabenda<sup>19</sup>, Bernard Chasekwa<sup>10</sup>, Loty Diop<sup>6</sup>, Sherlie Jean-Louis Dulience<sup>11</sup>, Kaniz  
11 Jannat<sup>18</sup>, Chiza Kumwenda<sup>20</sup>, Anna Lartey<sup>3</sup>, Agnes Le Port<sup>22</sup>, Jef L Leroy<sup>6</sup>, Charles  
12 Mangani<sup>13</sup>, Susana Matias<sup>23</sup>, Malay Kanti Mridha<sup>24</sup>, Robert Ntozini<sup>10</sup>, Harriet Okronipa<sup>25</sup>,  
13 Jean-Bosco Ouedraogo<sup>26,27</sup>, John Phuka<sup>13</sup>, Mahbubur Rahman<sup>18,19</sup>, Lisy  
14 Ratsifandrihamana<sup>28</sup>, Saijuddin Shaikh<sup>17</sup>, Abu Ahmed Shamim<sup>24</sup>, Naume Tavengwa<sup>10</sup>,  
15 Mariama Touré<sup>6</sup>, Patricia Wolff<sup>29</sup>, Tarik Benmarhnia<sup>30,31</sup>, Christine P. Stewart<sup>2</sup>, Kathryn G.  
16 Dewey<sup>2</sup>, Benjamin F. Arnold<sup>1</sup>  
17

- 18 1. Francis I. Proctor Foundation and the Department of Ophthalmology, University of  
19 California, San Francisco, San Francisco, CA, USA  
20 2. Institute for Global Nutrition & Department of Nutrition, University of California Davis,  
21 Davis, CA, USA  
22 3. Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana  
23 4. Center for Child, Adolescent and Maternal Health Research, Faculty of Medicine and  
24 Health Technology, Tampere University, Tampere, Finland  
25 5. Department of Paediatrics, Tampere University Hospital, Tampere, Finland  
26 6. Nutrition, Diets and Health Unit, International Food Policy Research Institute,  
27 Washington, DC, USA  
28 7. Program in Human Nutrition, Department of International Health, Johns Hopkins  
29 Bloomberg School of Public Health, Baltimore, MD, USA  
30 8. School of Public Health, University of California, Berkeley, Berkeley, CA, USA  
31 9. Development Research Group, World Bank, Washington, DC, USA  
32 10. Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe  
33 11. School of Public Health, Washington University in St. Louis, St Louis, MO, USA  
34 12. Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford,  
35 CA, USA  
36 13. Department of Nutrition and Dietetics, School of Global and Public Health, Kamuzu  
37 University of Health Sciences Malawi, Blantyre, Malawi  
38 14. Mathematica, Washington, DC, USA  
39 15. Blizard Institute, Queen Mary University of London, London, United Kingdom  
40 16. Division of Biostatistics, Epidemiology and Environmental Health, School of Public  
41 Health, University of Nevada, Reno, Reno, NV, USA  
42 17. The JiVitA Project, Johns Hopkins University Bangladesh, Paschim Para, Gaibandha,  
43 Bangladesh  
44 18. Environmental Health and WASH, International Centre for Diarrhoeal Disease Research,  
45 Bangladesh (icddr,b), Dhaka  
46 19. Global Health and Migration Unit, Department of Women's and Children's Health,  
47 Uppsala University, Sweden  
48 20. World Health Organization, Geneva, Switzerland  
49 21. Department of Food Science and Nutrition, The University of Zambia, Lusaka, Zambia  
50 22. UMR MoISA, French National Research Institute for Sustainable Development (IRD),  
51 Montpellier, France

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 52 23. Department of Nutritional Sciences and Toxicology, University of California, Berkeley,  
53 Berkeley, CA, USA  
54 24. Centre for Non-communicable Diseases and Nutrition, BRAC James P Grant School of  
55 Public Health, BRAC University, Dhaka, Bangladesh  
56 25. Department of Nutritional Sciences, Oklahoma State University, Stillwater, OK, USA  
57 26. Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso  
58 27. Institut des Sciences et Techniques, Bobo-Dioulasso, Burkina Faso  
59 28. Centre Médico-Educatif 'Les Orchidées Blanches', Antananarivo, Madagascar  
60 29. Meds & Food for Kids, St. Louis, Missouri, USA  
61 30. Scripps Institution of Oceanography, University of California, San Diego, 8885 Biological  
62 Grade, La Jolla, CA 92037, USA  
63 31. Irset Institut de Recherche en Santé, Environnement et Travail, UMR-S 1085, Inserm,  
64 University of Rennes, EHESP, Rennes, France  
65

66  
67 **\*Corresponding author:** Pearl Anne Ante-Testard; Francis I. Proctor Foundation and the  
68 Department of Ophthalmology, University of California, San Francisco, San Francisco, CA,  
69 USA; [pearl.ante@ucsf.edu](mailto:pearl.ante@ucsf.edu).  
70

71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93

94 **Abstract**

95

96 Undernutrition in early childhood causes stunted growth, cognitive delays, and anemia, with  
97 effects often magnified among children from the poorest households. Small-quantity lipid-  
98 based nutrient supplements (SQ-LNS) are effective in addressing undernutrition and  
99 improving child development. As momentum builds to scale up SQ-LNS for children aged 6-  
100 24 months in the Global South, a key concern is achieving equity in its distribution and  
101 outcomes. We performed equity analysis of individual participant data from 14 randomized  
102 controlled trials in nine countries (N=37,707 children) to assess SQ-LNS effects on child  
103 growth, development, and anemia across levels of an international wealth index. Benefits of  
104 SQ-LNS were consistent across the wealth spectrum, leading to similar improvements in child  
105 growth, development, and anemia regardless of wealth. However, such equal benefits of SQ-  
106 LNS did not erase large inequalities in child growth and development between the poorest and  
107 wealthier households.

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129 **Main**

130

131 Undernutrition remains a global health crisis affecting children worldwide<sup>1</sup>. According to the  
132 United Nations International Children's Fund (UNICEF), 440 million children, two-thirds of the  
133 world's children under the age of five, do not consume diverse diets that provide sufficient  
134 nutrients necessary for healthy growth and development<sup>2</sup>. Nutrition in the first two years of life  
135 is especially critical, yet only one in three children aged 6-23 months receives the minimum  
136 required dietary diversity<sup>3</sup>. In 2022, the World Health Organization (WHO) reported that  
137 approximately 148 million children suffered from stunting, while 45 million experienced wasting  
138 at any given time; both conditions can be caused by undernutrition<sup>4,5</sup>. Undernutrition hinders  
139 children from reaching their full potential and, in extreme cases, can be life-threatening. Nearly  
140 half of all deaths among children under five are linked to undernutrition<sup>6</sup>.

141

142 Inadequate intake of essential nutrients during pregnancy<sup>7-9</sup> and early childhood can have  
143 severe consequences, posing risks to child survival, physical growth<sup>10</sup>, and neurobehavioral  
144 development<sup>2</sup>. The impact of undernutrition on these acute and long-term outcomes may be  
145 worsened by poverty, as individuals in the poorest households are consistently at higher risk  
146 of infectious diseases, antimicrobial resistance, and delayed vaccination<sup>11</sup>. Wealthier  
147 households tend to have more resources and time for activities that improve health such as  
148 access to healthy food<sup>12,13</sup> and access to activities that improve health<sup>12</sup>, while poorer  
149 households often face poor diets<sup>13</sup>.

150

151 Sustainable Development Goal 2.2 aims to address undernutrition<sup>14</sup>. One potential preventive  
152 intervention is the provision of small-quantity lipid-based nutrient supplements (SQ-LNS) to  
153 complement the diets of children aged 6-23 months<sup>15</sup>. SQ-LNS is a paste that provides about  
154 120 kcal (about four teaspoons) per day, and is designed to fortify children's diets to prevent  
155 undernutrition by supplementing, not replacing, human milk and locally available nutrient-rich  
156 foods<sup>15</sup>. Its base typically includes vegetable oil rich in omega-3 fatty acids, legumes (e.g.,  
157 peanuts, chickpeas, lentils, or soybeans), milk powder, and a small amount of sugar. The  
158 formulation is fortified with 22 vitamins and minerals at levels close to the daily recommended  
159 intake of these nutrients for children 6-24 months of age. SQ-LNS provision leads to improved  
160 linear growth, ponderal growth, cognitive development, and reduced anemia prevalence  
161 among children 6-24 months old<sup>16-19</sup> without displacing breast milk<sup>20</sup>. The strength of evidence  
162 based on a meta-analysis of randomized controlled trials (RCTs) has led to a recommendation  
163 by the World Bank to scale up SQ-LNS for children aged 6-24 months<sup>21</sup> in the Global South<sup>22</sup>.  
164 Since poorer and wealthier households may differ in how they access and engage with

165 interventions<sup>23,24</sup>, it is critical to assess these disparities as global initiatives consider scaling  
166 up SQ-LNS to ensure that children in need are effectively reached. Delivering blanket  
167 supplementation to entire populations is often expensive and logistically challenging, making  
168 it essential to explore equitable distribution strategies that result in greatest benefit—  
169 recognizing that the potential to benefit may not always align with the level of need<sup>25</sup>.

170  
171 Here, we conducted an individual participant data analysis of 14 RCTs that studied the effects  
172 of SQ-LNS on child growth and development outcomes<sup>26–39</sup>. Previous analyses of the impact  
173 of SQ-LNS investigated several dimensions of effect modification, including socioeconomic  
174 status, but for that factor only considered above- and below- within-study median household  
175 wealth based on individual study asset indices<sup>16–18</sup>. Our objectives were to compute more  
176 granular, internationally standardized measures of wealth across the trials to: (i) assess  
177 inequalities in child achieved growth and development and anemia by wealth standard and (ii)  
178 estimate the effect of SQ-LNS on those outcomes across varying levels of wealth standards.

179  
180 Throughout this study, we use the term *inequality* to refer to systematic differences in  
181 outcomes between individuals or groups, without implying a value judgment regarding  
182 fairness<sup>40</sup>. In contrast, *inequity* refers to differences that are considered avoidable and unjust.  
183 As defined by WHO, *equity* is the absence of avoidable disparities among socially,  
184 geographically, economically, or demographically defined groups<sup>41</sup>. In our analysis, *inequality*  
185 is used when reporting objectively measured differences in benefits and outcomes, whereas  
186 *equity* and *inequity* were used to interpret the implications of these differences.

187

## 188 **Results**

189

### 190 ***Characteristics of the RCTs included in the study***

191 We built on a previous meta-analyses of 14 prospective RCTs of SQ-LNS administered to  
192 infants and young children aged 6-24 months<sup>26–39</sup> (**Table 1**). The trials were conducted in sub-  
193 Saharan Africa (Burkina Faso, Ghana, Kenya, Madagascar, Malawi, Mali, and Zimbabwe; 10  
194 trials), Bangladesh (three trials), and Haiti (one trial). Of the 14 studies included, eight were  
195 efficacy trials, and six were effectiveness trials. Most studies used a cluster-randomized  
196 design except for Ghana, Haiti, DYAD-Ghana (DYAD-G), DYAD-Malawi (DYAD-M), and  
197 DOSE, which were individually randomized. Overall, this analysis included 37,707 infants and  
198 young children aged 6-24 months.

199 The primary analyses compared outcomes between children who received SQ-LNS (defined  
200 as LNS providing ~120 kcal per day, hereafter SQ-LNS) versus no intervention or an  
201 intervention that did not include any form of LNS or child supplementation (hereafter, control).  
202 Consistent with prior analyses<sup>16</sup>, study arms that included provision of maternal SQ-LNS, in  
203 addition to child SQ-LNS (**Table 1**), were excluded from the primary analysis but were included  
204 in sensitivity analyses, with results that were consistent with the primary analysis (**Text S1**),  
205 except for socioemotional scores.

206

### 207 ***Harmonized measures of wealth across trials***

208 We used the International Wealth Index (IWI) as our main indicator of wealth. The IWI is a  
209 harmonized composite measure of the level of material wellbeing or standard of living of  
210 households using 12 asset-based variables with 20 indicators in total<sup>42</sup> reflecting ownership of  
211 durables, housing quality, and access to public services (**Text S2**). Details on how the IWI was  
212 constructed is in the **Methods**. The distribution of asset variables and indicators was balanced  
213 between the control and SQ-LNS groups (**Tables S2A and S3A**, respectively). The IWI was  
214 harmonized and successfully constructed across all studies, allowing for consistent  
215 comparison of socioeconomic status despite differences in study settings. In most studies,  
216 the ownership of asset variables (e.g., TV, phone and car) increased with higher IWI levels  
217 (**Tables S3A and S3B**). The wealthier households were more likely to own high-quality assets  
218 (e.g., high-quality water source), whereas the poorest households predominantly owned  
219 lower-quality assets (e.g., low-quality water source). The aggregate distribution of the IWI  
220 across studies was unimodal, with overlap across studies for most of the distributions (**Fig. 1**).  
221 While models were fit using the full range of the IWI (0–100), predictions were restricted to IWI  
222 values between 0 and 70, as relatively few children had IWI scores  $\geq 70$ . We focused on this  
223 range of common support—the area where the IWI distributions across studies overlap for  
224 subsequent effect measure modification analyses. All studies were conducted in deprived  
225 settings. Thus, *wealthier* children signify relatively less poor than the poorest.

226

### 227 ***Measurement of child growth, development, and anemia***

228 Growth outcomes were assessed as continuous measures, including the length-for-age z-  
229 score (LAZ) and weight-for-length z-score (WLZ), and as binary measures, such as stunting  
230 (LAZ < -2 standard deviation), wasting (WLZ < -2 SD), and severe stunting (LAZ < -3 SD). We  
231 excluded severe wasting (WLZ < -3 SD) as an outcome because of the very small number of  
232 events across the studies (**Fig. S11 and S12**). Development outcomes were evaluated using  
233 continuous scores for language, gross and fine motor skills, executive function, and  
234 socioemotional skills. The z-scores were standardized within each study by regressing the raw  
235 score on child age and sex, and calculating the standardized residuals with further details

236 published previously<sup>17</sup>. Anemia outcomes were measured as a continuous outcome through  
237 blood hemoglobin concentration (g/L), and as a binary outcome defined as blood hemoglobin  
238 concentration < 110 g/L to define anemia.

239

240 Overall, children who received SQ-LNS showed better outcomes than those who did not in  
241 most studies, but substantial growth deficits remained based on WHO growth standards.  
242 Across the 14 studies, child growth, development, and anemia outcomes at endline varied  
243 substantially, with SQ-LNS groups generally showing modest improvements over control  
244 groups. Further details are provided in **Text S3**.

245

### 246 ***Wealth inequalities in adverse child outcomes across studies***

247 We hypothesized that children from wealthier households would have better growth,  
248 development, and anemia status compared to children from poorer households. To evaluate  
249 relative and absolute inequalities in adverse child outcomes (stunting, wasting, severe  
250 stunting, and anemia), we calculated the relative index of inequality (RII) and slope index of  
251 inequality (SII) for each binary outcome in each study, stratified by study arm. An RII > 1 (and  
252 95% CI does not include 1) and an SII > 0 (and 95% CI does not include 0) indicate relative  
253 and absolute inequalities that favor wealthier households (i.e., adverse child outcomes were  
254 more prevalent among the poorer children). Conversely, an RII < 1 (and 95% CI does not  
255 include 1) and an SII < 0 (and 95% CI does not include 0) signify that these adverse outcomes  
256 are more prevalent among wealthier children. An RII with a 95% CI that includes 1 and an SII  
257 with a 95% CI that includes 0 reflect non-significant relative and absolute inequalities.

258

259 Overall, on a relative scale (**Fig. 2A**), we observed IWI-related inequalities in both study arms,  
260 with stunting, wasting, and severe stunting more prevalent among children born in the poorer  
261 households (RII and 95% CI > 1). In contrast, no significant inequalities were observed for  
262 anemia in either of the study arms (RII and 95% CI: 1). On the absolute scale (**Fig. 2B**), a  
263 similar pattern emerged, with absolute wealth inequalities in stunting, wasting, and severe  
264 stunting disproportionately affecting poorer participants (SII and 95% CI, > 0). Study-specific  
265 inequalities are detailed in **Text S4**.

266

### 267 ***Effect of SQ-LNS interventions across the wealth gradient***

268 We hypothesized that that the benefits due to SQ-LNS would be larger among children in the  
269 poorer households (lower levels of the IWI). SQ-LNS provides essential micronutrients that  
270 may be particularly beneficial for children in the poorer households, where growth and  
271 development deficiencies are more prevalent, offering greater potential to benefit. We  
272 estimated the mean outcomes by intervention group and continuous IWI in each study using

273 splines in generalized additive models (**Fig. 3A**), and then pooled group-specific means (**Fig.**  
274 **3B**) and differences (**Fig. 3C**) across studies using pointwise random-effects meta-analyses<sup>43</sup>.  
275 Spline fits for each study and child outcome are provided in the Supplementary Materials (**Text**  
276 **S1**).

277

278 Overall, the SQ-LNS intervention significantly improved child growth outcomes, and the  
279 pooled mean LAZ and WLZ in children who received SQ-LNS were higher than those in the  
280 control group across all values of IWI (the estimates for stunting, wasting and severe stunting  
281 in SQ-LNS were generally below those of the control) (**Fig. 4**). The pooled differences between  
282 the SQ-LNS and control groups were generally constant across the IWI range (pooled  
283 interaction p-values >0.05). When accounting for the nonlinearity of the effects using splines,  
284 we observed point estimates suggesting greater SQ-LNS benefits on WLZ among children  
285 with higher IWI, with a similar but less pronounced pattern for LAZ and stunting, although the  
286 interaction p-values were not significant. Meanwhile, the effects of SQ-LNS on wasting and  
287 severe stunting showed no clear pattern across levels of IWI.

288

289 We observed better language, gross motor, fine motor, and socioemotional scores among the  
290 children who received SQ-LNS, and the pooled mean outcomes were generally higher than  
291 those of the control group across the IWI range (**Fig. 5**). Pooled intervention effects did not  
292 differ significantly across the IWI range (pooled interaction p-values >0.05) except for  
293 socioemotional scores, for which there were increasing benefits as IWI increased (pooled  
294 interaction p-value = 0.046, excluded maternal SQ-LNS supplementation) (**Table S1, Fig.**  
295 **S21**).

296

297 In general, SQ-LNS significantly improved the mean hemoglobin concentration and reduced  
298 anemia prevalence (**Fig. 6**). Consistent with the findings for growth and most of the  
299 development outcomes, the pooled intervention effect did not vary by wealth (pooled  
300 interaction p-values >0.05).

301

### 302 ***Additional analysis using sex-stratified data***

303

#### 304 *Wealth inequalities in adverse child outcomes across studies stratified by sex*

305 We found relative and absolute wealth inequalities in stunting, wasting and severe stunting  
306 among both girls and boys, and these inequalities did not appear to differ by sex. No significant  
307 wealth inequalities were found for anemia for either girls or boys (**Text S5**).

308

#### 309 *Effect of SQ-LNS on different child outcomes by wealth stratified by sex*

310 The SQ-LNS intervention significantly improved the growth, development, and anemia  
311 outcomes in both sexes (**Text S5**). Among girls, the pooled intervention effect between SQ-  
312 LNS and the control group did not vary by wealth for any child outcome (pooled interaction p-  
313 values >0.05). In contrast, among boys, the intervention effect varied significantly across the  
314 IWI range for WLZ (pooled interaction p-value = 0.048) and socioemotional scores (pooled  
315 interaction p-value = 0.020), indicating that boys from households with higher IWI had greater  
316 benefits from SQ-LNS.

317

### 318 ***Additional analysis using maternal education as socioeconomic indicator***

319 Since the wealth index captures an asset-related dimension of socioeconomic status, we used  
320 maternal education in an additional analysis (**Table S5**). Here, we used a categorical variable  
321 for maternal education: no formal education (none and incomplete primary), intermediate  
322 education (complete primary and incomplete secondary), and secondary and higher  
323 education. We observed results similar to those obtained using IWI. Further details are  
324 provided in **Text S6**.

## 325 **Discussion**

326 This individual participant data meta-analysis demonstrated consistent benefits of SQ-LNS for  
327 child growth, development, and anemia outcomes across wealth levels. Despite the large  
328 gradients between the poorest and wealthier children in attained growth and development  
329 outcomes, SQ-LNS appears to benefit children similarly compared to controls across the  
330 wealth spectrum. These results underscore: (i) the large level of inequalities between the  
331 poorest and wealthier children in their growth and development in low-income communities in  
332 the trials, (ii) that SQ-LNS would benefit all children by a similar magnitude regardless of their  
333 current wealth in settings where children experience nutrition deficits, and (iii) that the  
334 magnitude of improvement due to SQ-LNS, while important and significant, is far smaller than  
335 the observed gradient between the poorest and wealthier children. It is important to note that  
336 these studies were conducted in largely poor, rural communities and so the wealth differential  
337 is within those limited contexts, which may in part be why the benefit is seen across the wealth  
338 spectrum. Our results imply that programs focusing on poverty alleviation; infant and young  
339 child feeding; water, sanitation, and hygiene; promotion of girls' education and empowerment;  
340 maternal nutrition; and access to and quality of preventive and curative health cares are  
341 needed to help close the remaining gap.

342 Adherence to the intervention may vary by household wealth. If children from lower IWI  
343 households consumed smaller quantities of SQ-LNS, perhaps due to limited accessibility or

344 greater sharing within the household, this could attenuate effects in lower wealth groups under  
345 an intent-to-treat analysis. However, in this study, we found that adherence levels were  
346 generally similar across the IWI spectrum (**Fig. S42**). This suggests that the similar magnitude  
347 of effects of SQ-LNS at lower and higher IWI levels is not explained by differences in  
348 adherence across IWI levels.

349 We observed that SQ-LNS improved a child's growth and development to a level comparable  
350 to that of a child in a higher wealth bracket without changing any other element of household  
351 wealth. For example, in the case of LAZ (**Fig. 3B**), the mean LAZ for an IWI of 20 was  
352 approximately  $-1.5$  in the SQ-LNS group. A similar mean LAZ was observed in the control  
353 group at an IWI of approximately 40. An increase from 20 to 40 IWI represents a 50-  
354 percentage point increase in the wealth distribution of the study population. Achieving such a  
355 population-level shift in wealth would require complex, multifaceted interventions and policy  
356 reforms over a timescale of years to decades. Wealth, however, is only one component of a  
357 complex web of social and economic conditions that influence health across the life course.  
358 As such, increasing household wealth does not necessarily guarantee better child outcomes.  
359 Rather, wealth likely serves as a proxy for other underlying factors that more directly influence  
360 child health. In this context, SQ-LNS may provide a more immediate and potentially  
361 generalizable solution to directly improve most of the child growth and development outcomes  
362 in the near term. This result reinforces the potential of scaling up SQ-LNS as an intervention  
363 to improve child health outcomes in the Global South, helping to converge the health gap  
364 between poorer, healthier, and wealthier countries<sup>44</sup>.

365  
366 Despite the intervention resulted in a level shift of outcomes toward better level, this did not  
367 mitigate the wealth differential since the inequality measures in child outcomes were very  
368 similar in the intervention and control groups (**Fig. 2**) — latter may serve as proxy to pre-SQ-  
369 LNS status. Inequities may persist even within relatively poor communities. For example, an  
370 IWI of 0-20 compared to 61-70 represents a substantial difference in living conditions, and  
371 disparities in child outcomes between these levels are both avoidable and unjust if left  
372 unaddressed. If we want children in all wealth strata to have better nutritional status at similar  
373 levels, we would need complementary interventions that can further enhance child outcomes,  
374 while addressing inequities that SQ-LNS alone cannot overcome. For example, SQ-LNS can  
375 be integrated with complementary interventions such as vaccination, frequent screening for  
376 wasting, and others<sup>34,35,45</sup>. Given its economic value, SQ-LNS can serve as both a nutritional  
377 intervention and an incentive to encourage participation in these programmatic components  
378 to reduce costs and create a synergistic effect, especially if universal implementation is  
379 unsustainable. Evidence from several case studies has shown that SQ-LNS provision can be

380 highly cost-effective if well implemented<sup>46</sup>, particularly when delivered alongside behavior  
381 change communication (BCC) and screening. One study found that integrating SQ-LNS with  
382 BCC and screening reduced the unit cost per child contact for these services by more than  
383 the unit cost of SQ-LNS itself<sup>47</sup>. This suggests that SQ-LNS can serve as an effective incentive  
384 to increase uptake and efficiency of BCC and screening, compared to delivering BCC and  
385 screening alone, which was associated with significantly higher unit costs. In the PROMIS  
386 studies, SQ-LNS was offered alongside wasting screening to ensure that more children with  
387 severe or moderate acute malnutrition would be identified and referred to treatment services  
388 faster, creating a possible synergistic effect between prevention and screening/ treatment<sup>34,35</sup>.  
389 Another example that is following a similar approach is the NutriVax Project which has  
390 integrated SQ-LNS with vaccination programs<sup>45</sup>. Vaccination not only protects against  
391 infections that impair growth and development<sup>48</sup> but can also serve as a touchpoint for  
392 reaching vulnerable populations with nutritional supplementation.

393  
394 Another critical opportunity is integration within climate-resilient nutrition programs, e.g.,  
395 targeted implementation of SQ-LNS during periods of heightened vulnerability, such as the  
396 hunger season or in regions experiencing food insecurity. Climate change is already  
397 threatening global food systems as rising temperatures, extreme weather events, and  
398 increased frequency of natural disasters are reducing crop yields, lowering nutritional quality  
399 of foods, and limiting access to diverse and sufficient diets, particularly for poor and vulnerable  
400 populations<sup>49</sup>. It is projected that, between 2024 and 2050, climate change will result in 40  
401 million additional children with stunting and 28 million additional cases of wasting<sup>1,50</sup>.

402  
403 Overall, girls showed better growth outcomes than boys (**Fig. S31-S33**), which is consistent  
404 with a previous analysis of this data<sup>16</sup>. Some studies suggest that boys may be more  
405 biologically vulnerable than girls to adverse conditions in early life, which could limit their  
406 response to nutrition interventions<sup>51,52</sup>. For both sexes, we found no significant interaction  
407 between IWI and SQ-LNS for most of the outcomes. However, in boys, the impact of SQ-LNS  
408 on WLZ (**Fig. S39**) and socioemotional scores (**Fig. S40**) varied significantly by IWI, with  
409 children from households with higher IWI generally experiencing greater benefits. We also  
410 found that the overall effect of SQ-LNS (excluding maternal supplementation) on children's  
411 socioemotional scores increased with wealth. While both the linear regression line and spline  
412 showed a clear steep trend for WLZ, this pattern was less distinct for socioemotional scores,  
413 warranting caution in interpretation. Although boys' health outcomes have been linked to their  
414 mothers' diet and socioeconomic status<sup>52</sup>, and some evidence suggests preferential care-  
415 seeking for boys in wealthier families in some contexts compared to poorer households<sup>53</sup>, the  
416 underlying mechanisms driving these patterns remain unclear.

417

418 Consistent with prior findings, our results indicate that wealth does not significantly modify the  
419 effects of SQ-LNS on growth<sup>16</sup> or anemia<sup>18</sup>. However, previous analyses indicated significant  
420 effect modification by wealth for language, motor, and executive function scores, where  
421 greater effects of SQ-LNS were found among poorer households<sup>17</sup>. This discrepancy may be  
422 attributed to differences in the wealth indicators used. While the previous analyses relied on  
423 above- or below- median household wealth, this study used a continuous, standardized wealth  
424 index, which captures more nuanced, non-linear variations in effects across the entire wealth  
425 continuum. The same study also found no significant interaction between wealth and the  
426 binary development outcomes.

427 The current study had several limitations. First, in constructing the IWI, we used a formula  
428 adapted for three missing asset variables to account for studies with >3 missing variables  
429 which may have under-estimated the wealth scores. In a subset of studies, we also used the  
430 number of rooms in a household instead of the number of sleeping rooms in the construction  
431 of the IWI due to the limited data for the latter which may have led to an overestimation of  
432 wealth. Additionally, most trials were conducted in sub-Saharan Africa, with only three trials  
433 from Asia and one from the Caribbean, limiting the generalizability of the findings to other  
434 regions. Also, majority of the trials were generally performed in relatively low income  
435 communities within each country, thus, limiting generalizability to middle- and higher-income  
436 communities in those countries. Development and anemia outcomes were not available in  
437 some studies, reducing the statistical power for some analyses. Using wasting prevalence as  
438 an indicator may not fully capture the dynamic nature of the condition, and thus we may have  
439 missed important inequalities in wasting patterns.

440 Despite these limitations, the present study had several strengths. It included a large sample  
441 of high-quality RCTs across 14 diverse sites with varying geographic, socioeconomic, and  
442 health profiles. The included trials represent a mix of efficacy and effectiveness studies, which  
443 may have captured effects under both ideal and real-world conditions<sup>54</sup>. The use of a  
444 standardized IWI enhanced the comparability of wealth measures across studies, thereby  
445 improving the consistency and reliability of our analyses. Removing one or even two assets  
446 from the index was found to have minimal impact on household rankings, and excluding data  
447 from specific regions in the developing world did not significantly alter results<sup>42</sup>. The IWI also  
448 showed strong correlations with national Demographic and Health Surveys wealth indices,  
449 further supporting its validity<sup>42</sup>. It was also shown to be a strong predictor of child outcomes  
450 such as height-for-age z-scores and infant mortality<sup>55</sup>. Using maternal education instead of  
451 IWI gave similar results except for the hemoglobin concentration outcome, where we found a

452 significant interaction (maternal education × intervention) p-value using the one-stage meta-  
453 analysis (vs. when using a two-stage meta-analysis for each factor level). However, this should  
454 be interpreted with caution, as interaction terms in one-stage mixed-effects models may be  
455 susceptible to ecological bias, conflating within-study and cross-study effects<sup>43,56</sup>. Additionally,  
456 the 95% CIs for the two pooled interaction coefficients (intermediate × SQ-LNS and  
457 Secondary/Higher × SQ-LNS) derived from the two-stage meta-analysis overlapped,  
458 indicating no significant interactions.

459 In conclusion, we highlight large inequalities in growth and development outcomes between  
460 the poorest and wealthier children engaged in SQ-LNS trials across multiple countries, as well  
461 as the potential of SQ-LNS to benefit children across the wealth spectrum. While SQ-LNS  
462 demonstrated benefits in both low and higher wealth categories, these equal benefits were  
463 not sufficient to reduce existing inequalities in child outcomes. The mean impact of SQ-LNS  
464 is far smaller than the magnitude of existing inequalities across wealth strata, underscoring  
465 the need for additional complementary interventions. The findings also imply that if decision  
466 makers target an SQ-LNS intervention to the most disadvantaged populations, they should  
467 expect an impact on most child outcomes comparable to what is observed among wealthier  
468 populations not provided with the intervention. This study emphasizes the usefulness of  
469 incorporating an equity lens when evaluating intervention effects to ensure that “no child is left  
470 behind.”

471

472

473

474

475

476

477

478

479

## 480 **Methods**

### 481 ***Individual participant data***

482 We utilized individual participant data previously collated for a prior analysis<sup>25</sup>, encompassing  
483 14 prospective studies of small-quantity lipid-based nutrient supplements (SQ-LNS) provided  
484 to children aged 6-24 months. Eligible trials were individual or cluster randomized controlled  
485 trials (RCTs) conducted in the Global South, featuring longitudinal or repeated cross-sectional  
486 data collection. The DOSE trial used a single set of randomization blocks as a technique for  
487 individual level randomization<sup>28</sup>. Trials provided SQ-LNS (<125 kcal/day) for at least three  
488 months during the age range of 6-24 months and reported at least one relevant outcome.

489  
490 The majority of trials initiated child SQ-LNS at 6 months of age, with a duration of 6–12 months,  
491 except for DYAD-G and DYAD-M, which also provided maternal SQ-LNS<sup>26–39</sup>. RDNS and  
492 MAHAY included arms with both child and maternal SQ-LNS as well as an arm with child SQ-  
493 LNS alone. Children were eligible if their age at baseline allowed them to receive the  
494 intervention (supplementation or control components) for at least 3 months between 6 and 24  
495 months of age (i.e. children who entered the study at >21 months of age were excluded from  
496 the analyses). Complete details of the individual participant data have been published  
497 elsewhere<sup>25</sup>. The SHINE trial was specifically designed to present the results separately for  
498 HIV-exposed and HIV-unexposed children; only HIV-unexposed children were included in this  
499 analysis. The two PROMIS trials in Burkina Faso and Mali included independent longitudinal  
500 cohorts and repeated cross-sectional samples. Thus, we present longitudinal and repeated  
501 cross-sectional findings as separate comparisons for each trial. The number of studies  
502 included in each analysis depended on the availability of the outcome of interest.

503  
504 The exclusion criteria were as follows: 1) trials limited to children with moderate or severe  
505 malnutrition where LNS was used for treatment rather than prevention; 2) trials conducted in  
506 hospitalized populations or among children with pre-existing diseases; or 3) trials where SQ-  
507 LNS was combined with additional food or nutrients within a single arm without a comparator  
508 group isolating the SQ-LNS effect.

509  
510 Trials with multiple SQ-LNS interventions (e.g., varying dosages or formulations), those  
511 combining child SQ-LNS with maternal LNS supplementation, or those including non-  
512 nutritional interventions (e.g., Water, Sanitation and Handwashing) were included. Study arms  
513 involving non-LNS child supplementation (e.g., multiple micronutrient powders or fortified  
514 blended food) were excluded.

515

516 We conducted a complete case and intention-to-treat analysis.

517

### 518 ***Defining the intervention***

519 All arms providing SQ-LNS were combined into one intervention group (SQ-LNS), whereas  
520 non-LNS arms (no LNS for mother or child) were grouped into a single comparator group  
521 (hereafter, control).

522

523 Study arms that provided maternal SQ-LNS supplementation in addition to child SQ-LNS  
524 (**Table 1**) were excluded from the primary analysis but were included in the secondary  
525 analysis. This distinction was made because maternal SQ-LNS supplementation as compared  
526 to iron and folic acid supplementation has been shown to independently benefit infant and  
527 young child growth by improving birth weight and birth length as well as reducing the incidence  
528 of small-for-gestational-age births and newborn stunting<sup>57</sup>. However, the results of the primary  
529 analysis were consistent with those of maternal sensitivity analysis (**Text S1**). To maximize  
530 the study inclusion and participant sample size, in alignment with previous IPD analyses, we  
531 present the findings from the secondary analysis as the main results.

532

### 533 ***Defining the outcomes of interest***

534 The outcomes of interest in this study included growth, development, and anemia measures  
535 at the endline. Endline was defined as the main post-intervention time point for trials with less  
536 frequent child assessments or as the age nearest to the end of the supplementation period for  
537 trials with monthly assessments<sup>16</sup>. Growth outcomes were assessed continuously, using  
538 length-for-age z-scores (LAZ) and weight-for-length z-scores (WLZ), and as binary indicators,  
539 including stunting (LAZ < -2 standard deviation), wasting (WLZ < -2 SD), and severe stunting  
540 (LAZ < -3 SD). We excluded severe wasting (WLZ < -3 SD) due to very small number of events  
541 across studies (**Fig. S11 and S12**). Development outcomes were evaluated using continuous  
542 scores for language, motor function (gross and fine), executive function, and socioemotional  
543 scores. The z-scores were standardized within each study by regressing the raw development  
544 scores on child age and sex to obtain standardized residuals, analogous to LAZ in  
545 representing deviations from the mean for a given age and sex in SD units, but calculated  
546 relative to within-study distribution rather than external standard<sup>17</sup>. The measures and tools  
547 used have been described and published elsewhere<sup>17</sup>. For anemia, hemoglobin concentration  
548 (g/L) was measured as a continuous variable, whereas anemia status was classified as a  
549 binary outcome (hemoglobin < 110 g/L).

550

### 551 ***Defining the effect modifier***

552 The International Wealth Index (IWI) was first introduced by the Global Data Lab  
553 (<https://globaldatalab.org/iwi/computing/>) as a composite measure of household wealth using  
554 12 asset-based variables<sup>42</sup>. These variables reflect the ownership of consumer goods (such  
555 as a TV, refrigerator, phone, car, bicycle), cheap items (e.g., basic furniture such as chairs),  
556 expensive items (e.g., air conditioners), household characteristics (including flooring material,  
557 toilet facilities, and number of rooms), and access to public utilities such as electricity and  
558 water.

559  
560 In total, the IWI consists of 20 indicators: eight related to ownership of consumer durables and  
561 electricity access; nine (grouped into three sets) assessing the quality of the water source,  
562 flooring material, and toilet facilities; and three measuring the number of rooms in the  
563 household. In constructing the IWI, we collated the 12 asset-based variables for each study  
564 and recorded the variables using a similar categorization used by the Global Data Lab to  
565 harmonize them. We then ranked the households on the IWI scale, and its values for the 20  
566 indicators were included in the following formula:

567 
$$IWI = constant + \Sigma(W_n \cdot X_n),$$

568 where  $X_n$  is the asset indicator variable of the  $n^{\text{th}}$  asset and  $W_n$  is the estimated IWI weight of  
569 the  $n^{\text{th}}$  asset. The weights were derived through principal component analysis of these 12  
570 common assets and indicators in a pooled database of 165 household surveys from 1996 to  
571 2011 in 97 countries in the Global South, covering 2.1 million households<sup>42</sup>. The IWI scores  
572 ranged from 0 to 100. An IWI value of 0 is assigned to households lacking durable assets, no  
573 access to public services, and the lowest-quality housing. By contrast, a value of 100 is given  
574 to households that own all durable assets, have the best public utilities (such as electricity and  
575 water), and live in the highest-quality housing.

576  
577 The Global Data Lab tested its reliability as a comparable measure of household wealth<sup>42</sup>.  
578 Their findings indicate that removing one or even two assets from the index has a minimal  
579 impact on household rankings. Similarly, excluding data from specific regions in the  
580 developing world did not significantly alter the results. Within Demographic and Health Survey  
581 (DHS) countries, the IWI demonstrated high correlations with the national DHS wealth  
582 indices<sup>42</sup>. Additionally, their analysis showed that the 2.1 million households included in the  
583 dataset were evenly distributed across the IWI scale, avoiding issues such as clumping or  
584 truncation<sup>42</sup>.

585  
586 Some studies had missing asset variables for which we used separate formulas used by the  
587 Global Data Lab based on different combination of missing variable(s). Missing asset values  
588 were treated as zero, and the constants were adjusted based on the available variables.

589 Additionally, certain asset variables did not include the full range of quality levels (treated as  
590 dummy or indicator variables) (**Table S1B**). For instance, in JiVitA-4, the water source quality  
591 included only "low" and "medium" levels, with no "high" level, as defined by the Global Data  
592 Lab. In contrast, RDNS lacked a "low" quality level. We found that the IWI and study-specific  
593 wealth indices were highly correlated in the majority of studies (**Figure S27**). Therefore, we  
594 opted to use IWI in the main analysis.

595

596 We calculated the median and SD of the IWI and assessed the distribution of assets and  
597 indicators used in its construction by determining the number and percentage of participants  
598 owning each, stratified by study arm. Additionally, we evaluated asset ownership and indicator  
599 distribution across the IWI tertiles to explore the wealth gradient. We then plotted the  
600 distribution of IWI by study type.

601

## 602 **Statistical Analyses**

603

### 604 *Descriptive Statistics*

605 Before addressing these aims, we first assessed the mean child growth, development, and  
606 anemia measures attained at endline between study arms for each study.

607

### 608 *Assessing wealth inequalities in different adverse child outcomes across studies*

609 We estimated the relative and absolute inequalities for each binary adverse outcome in each  
610 study, stratified by study arms, by calculating the relative index of inequality (RII) and slope  
611 index of inequality (SII)<sup>58</sup>. These are regression-based indicators that are commonly used to  
612 measure health inequalities. Relative inequalities are typically greater when the overall  
613 prevalence of an outcome is low, whereas absolute inequalities are more pronounced at  
614 intermediate prevalence levels<sup>59</sup>. Reporting both relative and absolute inequalities is crucial  
615 as conclusions may differ based on the scales chosen<sup>60</sup>.

616

617 We restricted our analysis to binary adverse outcomes because the formulas for these  
618 indicators were specifically designed to accommodate binary data. The RII represents the ratio  
619 of the value at the bottom of the socioeconomic status (intercept) to the value at the top (slope  
620 + intercept), while the SII represents the difference between these values for binary outcomes.  
621 We used log-binomial regression for binary outcomes to model the association between  
622 participants' relative ranks in the cumulative distribution of the IWI deciles and each adverse  
623 child outcome. For cluster-randomized studies, clustering was accounted for by using robust  
624 standard errors. If log-binomial models failed to converge (for anemia), we used modified

625 Poisson regression with robust standard errors as an alternative. The Delta method was used  
626 to calculate the 95% CIs for the SII, while the Wald-type 95% CI was estimated for the RII.

627

628 Second, we pooled the RIIs and SIIs and their standard errors across studies using a random-  
629 effects meta-analysis to obtain pooled estimates and their 95% confidence intervals using the  
630 inverse variance method.

631

632 An RII  $> 1$  (and 95% CI does not include 1) and an SII  $> 0$  (and 95% CI does not include 0)  
633 indicate relative and absolute inequalities, respectively, where adverse child outcomes are  
634 more prevalent among children born in the poorest households. Conversely, an RII  $< 1$  (and  
635 95% CI does not include 1) and an SII  $< 0$  (and 95% CI does not include 0) signify that these  
636 adverse outcomes are more common among wealthier households. An RII (and 95% CI)  
637 including 1 and an SII (and 95% CI) including 0 reflect non-significant relative and absolute  
638 inequalities.

639

#### 640 *Estimating the effect of SQ-LNS on different child outcomes by wealth*

641 Following the original individual participant data meta-analyses, we used a two-stage  
642 hierarchical approach: a) first, we estimated the study-level effects derived from individual-  
643 level data for each trial; and b) second, we pooled estimates across the studies using a  
644 random-effect meta-analysis of the individual study spline fits.

645

646 To do this, we used pointwise meta-analysis<sup>43</sup>. In this approach, the predicted outcomes from  
647 the first stage are aggregated rather than regression coefficients. We aggregated the predicted  
648 outcomes for each value of X (i.e., IWI). We followed the approach of Belias et al. in conducting  
649 a two-stage pointwise meta-analysis<sup>43</sup>.

650

#### 651 *First stage:*

652 To assess the effect of the intervention on child outcomes by continuous IWI, we fitted a  
653 generalized additive model (GAM)<sup>61</sup> to capture potential nonlinear relationships between IWI  
654 and each child outcome. A common approach to investigating intervention effect modification  
655 is to model the interaction between a potential effect modifier and intervention<sup>43</sup>. In our  
656 analysis, we modeled the relationship between the effect modifier and outcome by including  
657 the spline-transformed modifier both as a main effect and in interaction with the intervention.  
658 We used the mgcv package in R to implement the GAM, which represents smooth functions  
659 using penalized regression splines (specifically, the cubic regression spline), with basis  
660 functions designed to be optimal<sup>62</sup>.

661

662 To avoid overfitting, we used a nonparametric smoother, the cubic regression spline<sup>63</sup>, fitting  
663 the model using restricted maximum likelihood (REML)<sup>64</sup>. We accounted for clustering in the  
664 cluster-randomized studies by incorporating cluster-level random effects. We applied the  
665 Gaussian family for continuous outcomes and the binomial family with a logit link for binary  
666 outcomes. Outcomes were estimated as a function of the IWI for each study and study arm,  
667 with the absolute risk difference and confidence intervals estimated per study across the IWI  
668 range. For binary outcomes, we back-transformed the predicted outcomes and absolute risk  
669 differences using an inverse logit function. Predictions were made conditional on IWI values  
670 between 0 and 70, because very few samples had an IWI of 70 or higher (**Fig. 1**).

671

672 *Second stage:*

673 In the second stage, we pooled both the predicted outcome curves for each study arm (on the  
674 identity scale for continuous outcomes and the logit scale for binary outcomes) and their  
675 absolute risk differences. This was performed using pointwise random-effects meta-analyses  
676 with REML estimators (and DerSimonian-Laird estimator when the model failed to converge).  
677 We then back-transformed the predicted binary outcomes using the inverse logit function.

678

679 *Pooled interaction p-value*

680 To assess whether the pooled intervention effect between the SQ-LNS and control arms (i.e.,  
681 difference due to SQ-LNS) was statistically different by IWI, we estimated the pooled p-value  
682 for the interaction.

683

684 First, for interpretability and simplicity, we fitted linear regressions to estimate the effect of SQ-  
685 LNS (versus control) on each child outcome (instead of using GAMs), including the interaction  
686 term between SQ-LNS (versus control) and IWI. For cluster-randomized studies, we  
687 accounted for clustering using robust standard errors, implemented via the `lm_robust` function  
688 from the `estimatr` package in R<sup>65</sup>.

689

690 Second, we extracted the coefficients and standard errors of the interaction terms from each  
691 study. These data were pooled using a random-effects meta-analysis with REML. Based on  
692 the pooled coefficients, we predicted child outcomes across the range of IWI (0-70) for both  
693 the SQ-LNS and control groups.

694

695 We calculated the pooled point estimates for the difference due to SQ-LNS in each child  
696 outcome across the range of IWI (i.e., 0-70) as follows:

697

698 Difference due to SQ-LNS =  $E[Y | \text{SQ-LNS, IWI}_{0-70}] - E[Y | \text{Control, IWI}_{0-70}]$

699 Difference due to SQ-LNS = (Pooled\_intercept + Pooled\_SQ-LNS × 1 + Pooled\_IWI × IWI<sub>0-70</sub> +  
700 Pooled\_IWI:SQ-LNS × 1 × IWI<sub>0-70</sub>) - (Pooled\_intercept + Pooled\_IWI × IWI<sub>0-70</sub>)

701

702 Difference due to SQ-LNS = Pooled\_SQ-LNS + Pooled\_IWI:SQ-LNS × IWI<sub>0-70</sub>

703

704 Finally, the pooled interaction p-value was derived from the random-effects meta-analysis,  
705 which represented the p-value for the pooled intervention effect.

706

### 707 *Sex-stratified analyses*

708 To account for potential differences in the effects of SQ-LNS on each child outcome based on  
709 sex, we stratified the data by child sex before estimating wealth inequalities in adverse child  
710 outcomes and the effects of SQ-LNS on child outcomes based on IWI. The analyses were  
711 repeated separately for girls and boys.

712

### 713 *Additional analysis using maternal education as socioeconomic indicator*

714 Since the wealth index captures a specific dimension of socioeconomic status, we used  
715 maternal education in an additional analysis. Maternal education is considered a reliable  
716 predictor of both short- and long-term child health and well-being<sup>66</sup>. We used the categorical  
717 variable of maternal education: no formal education (none and incomplete primary),  
718 intermediate (complete primary and incomplete secondary), and secondary and higher  
719 education. We assessed the interaction with the SQ-LNS intervention in two ways: (i)  
720 comparing models with and without the interaction term (maternal education × intervention)  
721 by fitting the models through a one-stage meta-analysis using the pooled data using Wald-  
722 type F test; and ii) fitting the model with interaction (maternal education × intervention) for  
723 each study and pooling each level of the interaction coefficients across studies for each child  
724 outcome using a random-effects meta-analysis.

725

726

727

728

729

730

731

732

733

734

735

736 **Inclusion and Ethics**

737 The original IPD meta-analysis protocol was registered with PROSPERO CRD42019146592  
738 (<https://www.crd.york.ac.uk/prospero>) and approved by the institutional review board of the  
739 University of California, Davis (1463609-1). Amendments to the protocol were approved by  
740 the same board (1463609-4). All individual trial protocols were approved by the respective  
741 institutional ethics committees.

742

743 **Data availability**

744 The pre-analysis plan is available through the Open Science Framework (OSF,  
745 <https://osf.io/c7f5g/>)<sup>67</sup>. The data will not be made available because they were compiled from  
746 14 different trials, with access controlled by the investigators of each trial.

747

748 **Code availability**

749 All analyses were conducted in R (version 4.3.3 “Angel Food Cake”). Codes and instructions  
750 to reproduce all analyses are available in the Open Science Framework (OSF,  
751 <https://osf.io/c7f5g/>)<sup>67</sup>.

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771 **References**

772

- 773 1. Bill and Melinda Gates Foundation Goalkeepers. The Race to Nourish a Warming World:  
774 Bill and Melinda Gates Foundation Goalkeepers 2024 Report. (2024).
- 775 2. United Nations Children’s Fund (UNICEF). *Child Food Poverty: Nutrition Deprivation in*  
776 *Early Childhood. Child Nutrition Report, 2024.* (2024).
- 777 3. UNICEF. Early childhood nutrition: Preventing malnutrition in infants and young  
778 children. <https://www.unicef.org/nutrition/early-childhood-nutrition>.
- 779 4. World Health Organization. Joint child malnutrition estimates.  
780 [https://www.who.int/data/gho/data/themes/topics/joint-child-malnutrition-estimates-](https://www.who.int/data/gho/data/themes/topics/joint-child-malnutrition-estimates-unicef-who-wb)  
781 [unicef-who-wb](https://www.who.int/data/gho/data/themes/topics/joint-child-malnutrition-estimates-unicef-who-wb) (2023).
- 782 5. World Health Organization. Malnutrition. [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/malnutrition)  
783 [sheets/detail/malnutrition](https://www.who.int/news-room/fact-sheets/detail/malnutrition) (2024).
- 784 6. United Nations Children’s Fund (UNICEF). Child Malnutrition.  
785 <https://data.unicef.org/topic/nutrition/malnutrition/> (2024).
- 786 7. Christian, P. & Stewart, C. P. Maternal Micronutrient Deficiency, Fetal Development, and  
787 the Risk of Chronic Disease. *J. Nutr.* **140**, 437–445 (2010).
- 788 8. Moreno-Fernandez, J., Ochoa, J. J., Lopez-Frias, M. & Diaz-Castro, J. Impact of Early  
789 Nutrition, Physical Activity and Sleep on the Fetal Programming of Disease in the  
790 Pregnancy: A Narrative Review. *Nutrients* **12**, 3900 (2020).
- 791 9. Namirembe, G. *et al.* Child stunting starts in utero: Growth trajectories and determinants in  
792 Ugandan infants. *Matern. Child. Nutr.* **18**, e13359 (2022).
- 793 10. Gonete, A. T., Kassahun, B., Mekonnen, E. G. & Takele, W. W. Stunting at birth and  
794 associated factors among newborns delivered at the University of Gondar Comprehensive  
795 Specialized Referral Hospital. *PLOS ONE* **16**, e0245528 (2021).

- 796 11. Ayorinde, A. *et al.* Health inequalities in infectious diseases: a systematic overview of  
797 reviews. *BMJ Open* **13**, e067429 (2023).
- 798 12. Hu, X., Wang, T., Huang, D., Wang, Y. & Li, Q. Impact of social class on health: The  
799 mediating role of health self-management. *PloS One* **16**, e0254692 (2021).
- 800 13. French, S. A., Tangney, C. C., Crane, M. M., Wang, Y. & Appelhans, B. M. Nutrition  
801 quality of food purchases varies by household income: the SHoPPER study. *BMC Public*  
802 *Health* **19**, 231 (2019).
- 803 14. United Nations. The Global Goals: 2 Zero Hunger.  
804 <https://www.globalgoals.org/goals/2-zero-hunger/>.
- 805 15. Aguayo, V. M. *et al.* Benefits of small-quantity lipid-based nutrient supplements for  
806 child nutrition and survival warrant moving to scale. *Nat. Food* (2023)  
807 doi:10.1038/s43016-023-00703-2.
- 808 16. Dewey, K. G. *et al.* Characteristics that modify the effect of small-quantity lipid-  
809 based nutrient supplementation on child growth: an individual participant data meta-  
810 analysis of randomized controlled trials. *Am. J. Clin. Nutr.* **114**, 15–42 (2021).
- 811 17. Prado, E. L. *et al.* Small-quantity lipid-based nutrient supplements for children age 6–  
812 24 months: a systematic review and individual participant data meta-analysis of effects on  
813 developmental outcomes and effect modifiers. *Am. J. Clin. Nutr.* **114**, 43–67 (2021).
- 814 18. Wessells, K. R. *et al.* Characteristics that modify the effect of small-quantity lipid-  
815 based nutrient supplementation on child anemia and micronutrient status: an individual  
816 participant data meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* **114**, 68–  
817 94 (2021).
- 818 19. Dewey, K. G. *et al.* Preventive small-quantity lipid-based nutrient supplements reduce  
819 severe wasting and severe stunting among young children: an individual participant data  
820 meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* **116**, 1314–1333 (2022).

- 821 20. Kumwenda, C. *et al.* Lipid-based nutrient supplements do not decrease breast milk  
822 intake of Malawian infants. *Am. J. Clin. Nutr.* **99**, 617–623 (2014).
- 823 21. Shekar, M., Shibata Okamura, K., Vilar-Compte, M., Dell’Aira, C., & eds. *Investment*  
824 *Framework for Nutrition 2024*. (Washington, DC: World Bank, 2024). doi:10.1596/42164.
- 825 22. Khan, T., Abimbola, S., Kyobutungi, C. & Pai, M. How we classify countries and  
826 people—and why it matters. *BMJ Glob. Health* **7**, e009704 (2022).
- 827 23. McMaughan, D. J., Oloruntoba, O. & Smith, M. L. Socioeconomic Status and Access  
828 to Healthcare: Interrelated Drivers for Healthy Aging. *Front. Public Health* **8**, 231 (2020).
- 829 24. White, M., Adams, J. & Heywood, P. How and why do interventions that increase  
830 health overall widen inequalities within populations? in *Social inequality and public health*  
831 (ed. Babones, S. J.) 64–81 (Policy Press, 2009).  
832 doi:10.1332/policypress/9781847423207.003.0005.
- 833 25. Dewey, K. G., Stewart, C. P., Wessells, K. R., Prado, E. L. & Arnold, C. D. Small-  
834 quantity lipid-based nutrient supplements for the prevention of child malnutrition and  
835 promotion of healthy development: overview of individual participant data meta-analysis  
836 and programmatic implications. *Am. J. Clin. Nutr.* **114**, 3–14 (2021).
- 837 26. Adu-Afarwuah, S. *et al.* Randomized comparison of 3 types of micronutrient  
838 supplements for home fortification of complementary foods in Ghana: effects on growth  
839 and motor development. *Am. J. Clin. Nutr.* **86**, 412–420 (2007).
- 840 27. Iannotti, L. L. *et al.* Linear growth increased in young children in an urban slum of  
841 Haiti: a randomized controlled trial of a lipid-based nutrient supplement. *Am. J. Clin. Nutr.*  
842 **99**, 198–208 (2014).
- 843 28. Maleta, K. M. *et al.* Provision of 10–40 g/d Lipid-Based Nutrient Supplements from 6  
844 to 18 Months of Age Does Not Prevent Linear Growth Faltering in Malawi. *J. Nutr.* **145**,  
845 1909–1915 (2015).

- 846 29. Adu-Afarwuah, S. *et al.* Small-quantity, lipid-based nutrient supplements provided to  
847 women during pregnancy and 6 mo postpartum and to their infants from 6 mo of age  
848 increase the mean attained length of 18-mo-old children in semi-urban Ghana: a  
849 randomized controlled trial, *Am. J. Clin. Nutr.* **104**, 797–808 (2016).
- 850 30. Ashorn, P. *et al.* Supplementation of Maternal Diets during Pregnancy and for 6  
851 Months Postpartum and Infant Diets Thereafter with Small-Quantity Lipid-Based Nutrient  
852 Supplements Does Not Promote Child Growth by 18 Months of Age in Rural Malawi: A  
853 Randomized Controlled Trial. *J. Nutr.* **145**, 1345–1353 (2015).
- 854 31. Hess, S. Y. *et al.* Small-Quantity Lipid-Based Nutrient Supplements, Regardless of  
855 Their Zinc Content, Increase Growth and Reduce the Prevalence of Stunting and Wasting  
856 in Young Burkinabe Children: A Cluster-Randomized Trial. *PLOS ONE* **10**, e0122242  
857 (2015).
- 858 32. Christian, P. *et al.* Effect of fortified complementary food supplementation on child  
859 growth in rural Bangladesh: a cluster-randomized trial. *Int. J. Epidemiol.* **44**, 1862–1876  
860 (2015).
- 861 33. Galasso, E., Weber, A. M., Stewart, C. P., Ratsifandrihamanana, L. & Fernald, L. C.  
862 H. Effects of nutritional supplementation and home visiting on growth and development in  
863 young children in Madagascar: a cluster-randomised controlled trial. *Lancet Glob. Health*  
864 **7**, e1257–e1268 (2019).
- 865 34. Becquey, E. *et al.* Impact on child acute malnutrition of integrating a preventive  
866 nutrition package into facility-based screening for acute malnutrition during well-baby  
867 consultation: A cluster-randomized controlled trial in Burkina Faso. *PLOS Med.* **16**,  
868 e1002877 (2019).

- 869 35. Huybregts, L. *et al.* Impact on child acute malnutrition of integrating small-quantity  
870 lipid-based nutrient supplements into community-level screening for acute malnutrition: A  
871 cluster-randomized controlled trial in Mali. *PLOS Med.* **16**, e1002892 (2019).
- 872 36. Dewey, K. G. *et al.* Lipid-based nutrient supplementation in the first 1000 d improves  
873 child growth in Bangladesh: a cluster-randomized effectiveness trial. *Am. J. Clin. Nutr.*  
874 **105**, 944–957 (2017).
- 875 37. Humphrey, J. H. *et al.* Independent and combined effects of improved water,  
876 sanitation, and hygiene, and improved complementary feeding, on child stunting and  
877 anaemia in rural Zimbabwe: a cluster-randomised trial. *Lancet Glob. Health* **7**, e132–e147  
878 (2019).
- 879 38. Luby, S. P. *et al.* Effects of water quality, sanitation, handwashing, and nutritional  
880 interventions on diarrhoea and child growth in rural Bangladesh: a cluster randomised  
881 controlled trial. *Lancet Glob. Health* **6**, e302–e315 (2018).
- 882 39. Null, C. *et al.* Effects of water quality, sanitation, handwashing, and nutritional  
883 interventions on diarrhoea and child growth in rural Kenya: a cluster-randomised  
884 controlled trial. *Lancet Glob. Health* **6**, e316–e329 (2018).
- 885 40. Arcaya, M. C., Arcaya, A. L. & Subramanian, S. V. Inequalities in health: definitions,  
886 concepts, and theories. *Glob. Health Action* **8**, 27106 (2015).
- 887 41. World Health Organization. Health Equity. [https://www.who.int/health-topics/health-](https://www.who.int/health-topics/health-equity#tab=tab_1)  
888 [equity#tab=tab\\_1](https://www.who.int/health-topics/health-equity#tab=tab_1).
- 889 42. Smits, J. & Steendijk, R. The International Wealth Index (IWI). *Soc. Indic. Res.* **122**,  
890 65–85 (2015).
- 891 43. Belias, M. *et al.* Predicting personalised absolute treatment effects in individual  
892 participant data meta-analysis: An introduction to splines. *Res. Synth. Methods* **13**, 255–  
893 283 (2022).

- 894 44. Jamison, D. T. *et al.* Global health 2035: a world converging within a generation. *The*  
895 *Lancet* **382**, 1898–1955 (2013).
- 896 45. Eleanor Crook Foundation. Why ECF and Gavi are joining forces to explore pairing  
897 nutritional supplement and vaccine delivery to save more lives.  
898 [https://eleanorcrookfoundation.org/resources/why-ecf-and-gavi-are-joining-forces-to-](https://eleanorcrookfoundation.org/resources/why-ecf-and-gavi-are-joining-forces-to-explore-pairing-nutritional-supplement-and-vaccine-delivery-to-save-more-lives/)  
899 [explore-pairing-nutritional-supplement-and-vaccine-delivery-to-save-more-lives/](https://eleanorcrookfoundation.org/resources/why-ecf-and-gavi-are-joining-forces-to-explore-pairing-nutritional-supplement-and-vaccine-delivery-to-save-more-lives/) (2023).
- 900 46. Working Group on Cost and Cost-effectiveness, SQ-LNS Task Force. Costs and Cost-  
901 effectiveness of Small-Quantity Lipid-based Nutrient Supplements.
- 902 47. Brander, R. L. *et al.* The Cost and Cost-Effectiveness of an Integrated Wasting  
903 Prevention and Screening Intervention Package in Burkina Faso and Mali. *J. Nutr.* **154**,  
904 2551–2565 (2024).
- 905 48. Nandi, A. & Shet, A. Why vaccines matter: understanding the broader health,  
906 economic, and child development benefits of routine vaccination. *Hum. Vaccines*  
907 *Immunother.* **16**, 1900–1904 (2020).
- 908 49. Mirzabaev, A. *et al.* Climate Change and Food Systems. in *Science and Innovations*  
909 *for Food Systems Transformation* (eds. Von Braun, J., Afsana, K., Fresco, L. O. & Hassan,  
910 M. H. A.) 511–529 (Springer International Publishing, Cham, 2023). doi:10.1007/978-3-  
911 031-15703-5\_27.
- 912 50. Institute for Health Metrics and Evaluation (IHME). Financing Global Health 2023:  
913 The Future of Health Financing in the Post-Pandemic Era. (2024).
- 914 51. Wells, J. C. K. *et al.* Beyond wasted and stunted—a major shift to fight child  
915 undernutrition. *Lancet Child Adolesc. Health* **3**, 831–834 (2019).
- 916 52. Eriksson, J. G., Kajantie, E., Osmond, C., Thornburg, K. & Barker, D. J. P. Boys live  
917 dangerously in the womb. *Am. J. Hum. Biol.* **22**, 330–335 (2010).

- 918 53. Weber, A. M. *et al.* Gender norms and health: insights from global survey data. *The*  
919 *Lancet* **393**, 2455–2468 (2019).
- 920 54. Porzsolt Franz, F. *et al.* Efficacy and effectiveness trials have different goals, use  
921 different tools, and generate different messages. *Pragmatic Obs. Res.* **47** (2015)  
922 doi:10.2147/POR.S89946.
- 923 55. Mayfour, K. W. & Hruschka, D. Assessing comparative asset-based measures of  
924 material wealth as predictors of physical growth and mortality. *SSM - Popul. Health* **17**,  
925 101065 (2022).
- 926 56. Fisher, D. J., Carpenter, J. R., Morris, T. P., Freeman, S. C. & Tierney, J. F. Meta-  
927 analytical methods to identify who benefits most from treatments: daft, deluded, or deft  
928 approach? *BMJ* **j573** (2017) doi:10.1136/bmj.j573.
- 929 57. Dewey, K. G. *et al.* Effects of prenatal small-quantity lipid-based nutrient  
930 supplements on pregnancy, birth, and infant outcomes: a systematic review and meta-  
931 analysis of individual participant data from randomized controlled trials in low- and  
932 middle-income countries. *Am. J. Clin. Nutr.* **120**, 814–835 (2024).
- 933 58. Mackenbach, J. P. & Kunst, A. E. Measuring the magnitude of socio-economic  
934 inequalities in health: An overview of available measures illustrated with two examples  
935 from Europe. *Soc. Sci. Med.* **44**, 757–771 (1997).
- 936 59. Houweling, T. A., Kunst, A. E., Huisman, M. & Mackenbach, J. P. Using relative and  
937 absolute measures for monitoring health inequalities: experiences from cross-national  
938 analyses on maternal and child health. *Int. J. Equity Health* **6**, 15 (2007).
- 939 60. King, N. B., Harper, S. & Young, M. E. Use of relative and absolute effect measures  
940 in reporting health inequalities: structured review. *BMJ* **345**, e5774–e5774 (2012).

- 941 61. Young, R. L., Weinberg, J., Vieira, V., Ozonoff, A. & Webster, T. F. Generalized  
942 additive models and inflated type I error rates of smoother significance tests. *Comput. Stat.*  
943 *Data Anal.* **55**, 366–374 (2011).
- 944 62. Wood, S. N. *Generalized Additive Models: An Introduction with R*. (Chapman and  
945 Hall/CRC, 2017). doi:10.1201/9781315370279.
- 946 63. Perperoglou, A., Sauerbrei, W., Abrahamowicz, M. & Schmid, M. A review of spline  
947 function procedures in R. *BMC Med. Res. Methodol.* **19**, 46 (2019).
- 948 64. Wood, S. N. Fast stable restricted maximum likelihood and marginal likelihood  
949 estimation of semiparametric generalized linear models: Estimation of Semiparametric  
950 Generalized Linear Models. *J. R. Stat. Soc. Ser. B Stat. Methodol.* **73**, 3–36 (2011).
- 951 65. DeclareDesign. Mathematical notes for estimatr.  
952 <https://declaredesign.org/r/estimatr/articles/mathematical-notes.html> (2024).
- 953 66. Prickett, K. C. & Augustine, J. M. Maternal Education and Investments in Children’s  
954 Health. *J. Marriage Fam.* **78**, 7–25 (2016).
- 955 67. Arnold, B. & Ante-Testard, P. A. Assessing the effect of small-quantity lipid-based  
956 nutrient supplements on child outcomes in an equity and planetary health lens: an analysis  
957 of individual participant data in the Global South. (2024) doi:10.17605/OSF.IO/C7F5G.  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968

969 **Acknowledgements**

970 The SQ-LNS individual participant data meta-analysis project was funded by the Bill and  
971 Melinda Gates Foundation to the University of California, Davis (OPP49817). This study also  
972 had additional support from the National Institute of Allergy and Infectious Diseases  
973 (R01AI166671 to B.F.A.).

974

975 **Author contributions**

976 P.A.A.-T. and B.F.A developed and drafted the statistical analysis plan with input from K.G.D.,  
977 C.P.S., C.D.A., K.R.W., L.H., S.P.L., E.G., T.B., A.J.P., and P.C.

978 P.A.A.-T. conducted the data analysis with input and guidance from B.F.A.

979 P.A.A.-T. constructed the tables and figures with input and guidance from B.F.A.; and input  
980 from K.G.D., C.D.A., C.P.S., and K.R.W.

981 K.R.W. and C.D.A. collated the data from all trials during the previous individual participant  
982 data meta-analysis. P.A.A.-T, C.D.A., and B.F.A. collected additional asset variables from  
983 relevant trials. Investigators from JiVitA-4, PROMIS-BF, iLiNS-Zinc, Ghana, DYAD-G, iLiNS-  
984 DOSE, PROMIS-Mali, and SHINE provided additional asset data for the construction of the  
985 international wealth index.

986 C.D.A. provided data resources. B.F.A. and C.D.A. provided statistical resources.

987 B.F.A. and K.G.D. provided guidance and supervision in the evolution of this study.

988 P.A.A.-T. wrote the initial draft of this manuscript with input and conceptual guidance from  
989 B.F.A.; and K.G.D., C.P.S., C.D.A., and K.R.W., helped in the interpretation of the preliminary  
990 results.

991 All authors contributed to the interpretation and subsequent revisions.

992 All authors read and approved the manuscript.

993

994 **Competing interests**

995 The authors declare no competing interests.

996

997

998

999

1000

1001

1002


1003

1004


**Table 1. Randomized controlled trials that were included in the individual participant data meta-analysis.**

Study Name	Study	Country	Type of study	Cluster-randomized	Child SQ-LNS Age at start in months (duration)	Maternal SQ-LNS	Children <sup>a</sup>
JiVitA-4	Christian 2015	Bangladesh	Efficacy	Y	6 (12)	N	4568
RDNS	Dewey 2017	Bangladesh	Effectiveness	Y	6 (18)	Y <sup>c</sup>	2567
WASH-B Bangladesh	Luby 2018	Bangladesh	Efficacy	Y (block)	6 (18)	N	4792
PROMIS-BF	Becquey 2019	Burkina Faso	Effectiveness	Y	6 (12)	N	1782
PROMIS-BF CS			Effectiveness Repeated cross-sectional				1157
iLiNS-Zinc	Hess 2015	Burkina Faso	Efficacy	Y	9 (9)	N	2647
Ghana	Adu Afarwuah 2007	Ghana	Effectiveness	N (individually randomized)	6 (6)	N	194
iLiNS-DYAD-G	Adu Afarwuah 2016	Ghana	Efficacy	N (individually randomized)	6 (12)	Y	1113
Haiti	Iannotti 2014	Haiti	Efficacy	N (individually randomized)	6-11 (6-12)	N	322
WASH-B Kenya	Null 2018	Kenya	Efficacy	Y	6 (18)	N	6815
MAHAY	Galasso 2019	Madagascar	Effectiveness	Y (community)	6-11 (6-12)	Y <sup>c</sup>	3438
iLiNS-DYAD-M	Ashorn 2015	Malawi	Efficacy	N (individually randomized)	6 (12)	Y	675
iLiNS-DOSE	Maleta 2015	Malawi	Efficacy	N <sup>b</sup>	6 (12)	N	1018
PROMIS-M	Huybregts 2019	Mali	Effectiveness	Y	6 (18)	N	1013
PROMIS-M CS			Effectiveness Repeated cross-sectional				1927
SHINE HIV-	Humphrey 2019	Zimbabwe	Effectiveness	Y	6 (12)	N	3679


<sup>a</sup> Including all variables of interest and excluding missing values for the intervention variable. SQ-LNS: Small quantity lipid-based nutrient supplement; N: no; <sup>b</sup> indicates that the study was individually-randomized using one set of randomization blocks; <sup>c</sup>: Indicates that the trial included at least one arm with maternal SQ-LNS combined with child SQ-LNS and at least one arm with child SQ-LNS alone.



**Fig. 1. Distribution of the International Wealth Index by study.** The International Wealth Index (IWI) is based on 12 household assets (i.e., 20 indicators in total) measured and weighted to provide a score between 0 (poorest) and 100 (wealthier). Overall, there were 37,605 children that contributed to the IWI distribution (excluding the missing values). The dashed line indicates an IWI value of 70. When fitting models to estimate effects, we included the whole range of the International Wealth Index (0-100), but predictions were made conditional on IWI values between 0 and 70, as few children had an  $IWI \geq 70$  (519 children from 11 studies, 1.4% of all measurements). For the stacked area plot, we binned the IWI values into intervals (bins) of 10 units, and calculated the number of children in each bin within each study.




**Fig. 2. Pooled Relative Index of Inequality and Slope Index of Inequality across studies for stunting, wasting, severe stunting at endline and anemia between intervention arms.** We restricted our analysis to binary outcomes for which the RII and SII are most clearly defined. The RII and SII quantify inequalities in relative and absolute scales, respectively. These are regression-based indicators which use all subgroups compared to a pairwise comparison that ignores other groups. To estimate these indices, we first ranked the individuals from the poorest to the wealthier in the cumulative distribution of the International Wealth Index deciles. **A.** The RII represents the ratio of the value at the bottom of the social hierarchy (poorest; intercept) to the value at the top (wealthier; slope + intercept). **B.** The SII represents the difference between these values. The SII point estimates and their 95% confidence intervals were multiplied by 100 to express them as percentage points. We used log-binomial regression to model the association between participants' relative rank in the cumulative distribution of the IWI deciles and the child outcome, and modified Poisson if log-binomial models failed to converge (anemia). The RIIs and SIIs and their standard errors were pooled across studies using random-effects meta-analysis. An RII > 1 (and 95% CI does not include 1) and an SII > 0 (and 95% CI does not include 0) indicate relative and absolute inequalities in which adverse child outcomes were more prevalent among the poorest households. Conversely, an RII < 1 (and 95% CI does not include 1) and an SII < 0 (and 95% CI does not include 0) signify that these adverse outcomes were more common among the wealthier households. An RII (and 95% CI) including 1 and an SII (and 95% CI) including 0 reflect no significant relative and absolute inequalities. Intervention included maternal supplementation. Error bars represent 95% confidence intervals.




**Fig. 3. The analysis estimated group specific means and pooled differences by wealth index using point-wise meta-analyses.** Example of the analysis process using length-for-age Z-score by International Wealth Index (IWI) and intervention group. **A.** Study-specific relationships between the IWI and length-for-age Z-scores (LAZ) by intervention group. **B.** Pooled estimates from a two-stage random effects meta-analysis of LAZ by IWI and intervention group across all studies in panel A. **C.** Pooled difference in LAZ between intervention groups over levels of IWI. Intervention effects conditional on IWI were estimated by subtracting the spline fits for the intervention group from the control group within each study. These effects were then pooled using pointwise random-effects meta-analysis with restricted maximum likelihood. In all panels, shaded bands represent 95% confidence intervals (CIs), while panels B and C specifically represent 95% pointwise CIs.

## Growth outcomes




**Fig. 4. Pooled child growth outcomes by intervention group and differences due to SQ-LNS. A.** Pooled length-for-age Z-score. **B.** Pooled weight-for-length Z-score. **C.** Pooled probability of stunting. **D.** Pooled probability of wasting. **E.** Pooled probability of severe stunting. We pooled the child growth outcomes for each intervention arm using pointwise random-effect meta-analysis with restricted maximum likelihood (REML). Intervention effects conditional on IWI were estimated by subtracting the spline fits for the intervention group from the control group within each study. These effects were then pooled using pointwise random-effects meta-analysis with REML. For the linear regression models (dashed lines), intervention effects were estimated by pooling the coefficients for the interaction term between IWI and intervention through random-effects meta-analysis and getting the difference between intervention groups. The pooled-p-for-interaction were from the random-effect meta-analysis of the pooled coefficients of interaction and standard errors across studies. Intervention included maternal supplementation. Shaded areas represent the 95% pointwise confidence intervals. The pooled estimates for length-for-age-Z-score are also noted in Fig. 3. Spline fits per study are found in the Supplementary Materials (Text S1).

## Development outcomes



**Fig. 5. Pooled child developmental outcomes by intervention group and differences due to SQ-LNS.** **A.** Pooled language score. **B.** Pooled gross motor score. **C.** Pooled fine motor score. **D.** Pooled executive function score. **E.** Pooled socioemotional score. We pooled the child development outcomes for each intervention arm using pointwise random-effect meta-analysis with restricted maximum likelihood (REML). Intervention effects conditional on IWI were estimated by subtracting the spline fits for the intervention group from the control group within each study. These effects were then pooled using pointwise random-effects meta-analysis with REML. For the linear regression models (dashed lines), intervention effects were estimated by pooling the coefficients for the interaction term between IWI and intervention through random-effects meta-analysis and getting the difference between intervention groups. The pooled-p-for-interaction were from the random-effect meta-analysis of the pooled coefficients of interaction and standard errors across studies. Intervention included maternal supplementation. Shaded areas represent the 95% pointwise confidence intervals. Development scores are internal to each study distribution of the study-specific indicator. Spline fits per study are found in the Supplementary Materials (Text S1).

## Anemia outcomes



**Fig. 6. Pooled child anemia outcomes by intervention group and differences due to SQ-LNS. A.** Pooled hemoglobin concentration. **B.** Pooled probability of anemia. We pooled the child hematological outcomes for each intervention arm using pointwise random-effect meta-analysis with restricted maximum likelihood (REML). Intervention effects conditional on IWI were estimated by subtracting the spline fits for the intervention group from the control group within each study. These effects were then pooled using pointwise random-effects meta-analysis with REML. For the linear regression models (dashed lines), intervention effects were estimated by pooling the coefficients for the interaction term between IWI and intervention through random-effects meta-analysis and getting the difference between intervention groups. The pooled-p-for-interaction were from the random-effect meta-analysis of the pooled coefficients of interaction and standard errors across studies. Intervention included maternal supplementation. Shaded areas represent the 95% pointwise confidence intervals. Spline fits per study are found in the Supplementary Materials (Text S1).